Status:
COMPLETED
BIOmarkers in Severe AsthMa Patients on Omalizumab Treatment
Lead Sponsor:
Medical University of Warsaw
Conditions:
Severe Asthma
Eligibility:
All Genders
18-70 years
Brief Summary
Eosinophil infiltration and degranulation in airways has been implicated in the pathology of asthma. Periostin is considered to be a marker of eosinophilic inflammation and is one of the highly expres...
Detailed Description
Anti-IgE (omalizumab) has been shown to be an effective add-on therapy for patients with allergic severe asthma. In this observational study patients aged over 18 year with uncontrolled severe persist...
Eligibility Criteria
Inclusion
- positive history of atopy
- serum total IgE level between 30 and 700 IU/ml
- body weight not more than 150 kg
- high dose of ICS and LABA
- a documented history of 2-6 exacerbations requiring treatment with systemic corticosteroids ( with \>15 mg/day prednisone or other medications at similar dose, for at least 3 days).
Exclusion
- smoking
- pregnancy
Key Trial Info
Start Date :
April 4 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2018
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03361111
Start Date
April 4 2013
End Date
December 30 2018
Last Update
October 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Joanna Hermanowicz-Salamon
Warsaw, Poland, 00-707